Bullish & Foolish
Full CTXR fundamentals All 466 on the Survival Watch

CTXRCitius Pharmaceuticals, Inc.

Is Citius Pharmaceuticals struggling financially?

Yes, by its own account. Citius Pharmaceuticals told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

5/100

Critical

Sector
Biotech/Pharma
Market cap
$16.5M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 2months

    If the burn speeds up

    Empty by Aug 2026

  • 4months

    If it eases off

    Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$17.0M

÷

Cash burned over the last 12 months

$62.2M

What Citius Pharmaceuticals told the SEC

…by risks and uncertainties related to: our independent registered public accounting firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; our need for substantial additional funds and our ability to raise those funds; our ongoing evaluation of strategic alternatives; our ability to regain compliance with the…

Citius Pharmaceuticals, Inc., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 158.8% share-count increase The company issued stock. Each share now owns 61.4% less of the business than a year ago, before any change in the price.
  • Cash burn is increasing It is spending 80% more cash per year than it was, so the runway above shortens even if nothing else changes.
  • Debt pressure is material Operating earnings cover only -142.5x the interest bill, so the interest is being met out of cash reserves rather than out of the business.

Other Biotech/Pharma companies that filed the doubt